| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FON.13.244 |
| P698 | PubMed publication ID | 24328407 |
| P2093 | author name string | Nadia Harbeck | |
| Flavio Solca | |||
| Thomas C Gauler | |||
| P2860 | cites work | A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab | Q24594725 |
| A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer | Q24626194 | ||
| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 | ||
| A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours | Q24653999 | ||
| ErbB receptors: from oncogenes to targeted cancer therapies | Q24683709 | ||
| Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. | Q40133869 | ||
| Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting | Q40236278 | ||
| Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. | Q40457478 | ||
| Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 | ||
| New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors | Q41127315 | ||
| XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. | Q42725846 | ||
| Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors | Q42948964 | ||
| Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer | Q43061055 | ||
| Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer | Q43270036 | ||
| Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma | Q45766942 | ||
| Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. | Q46086817 | ||
| Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study | Q46256397 | ||
| Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). | Q48315834 | ||
| Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). | Q54551051 | ||
| Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. | Q54590596 | ||
| Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. | Q54618926 | ||
| Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial | Q57278896 | ||
| The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors | Q27640631 | ||
| Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker | Q27681964 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy | Q27851461 | ||
| Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer | Q27851549 | ||
| Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer | Q27851553 | ||
| Human papillomavirus and survival of patients with oropharyngeal cancer. | Q27851567 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Q27851705 | ||
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 | ||
| Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial | Q27851751 | ||
| Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
| Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. | Q27852333 | ||
| Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. | Q27852408 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 | ||
| Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives | Q28289431 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study | Q33406802 | ||
| Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer | Q33810641 | ||
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. | Q33827808 | ||
| Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy | Q33828409 | ||
| Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias? | Q34116744 | ||
| New driver mutations in non-small-cell lung cancer | Q34161395 | ||
| Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial | Q34263959 | ||
| Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck | Q34287207 | ||
| Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase | Q34323951 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Q34620650 | ||
| The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck | Q34639763 | ||
| Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers | Q34760882 | ||
| Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate | Q34880994 | ||
| Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib | Q35592279 | ||
| A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. | Q35743883 | ||
| Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer | Q35977527 | ||
| Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations | Q35986801 | ||
| Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. | Q36185012 | ||
| New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). | Q36303845 | ||
| Herceptin: mechanisms of action and resistance | Q36386680 | ||
| Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited? | Q36458755 | ||
| A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors | Q36660463 | ||
| A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors | Q36660538 | ||
| Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. | Q36708974 | ||
| The chemoradiation paradigm in head and neck cancer | Q36747213 | ||
| Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors | Q36816522 | ||
| A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses | Q37054957 | ||
| Ligand-induced ErbB receptor dimerization | Q37154122 | ||
| Mechanisms of ErbB receptor negative regulation and relevance in cancer | Q37244805 | ||
| Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. | Q37379113 | ||
| The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine | Q37433324 | ||
| Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications | Q37622609 | ||
| Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer | Q37634598 | ||
| Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer | Q37653443 | ||
| EGFR mutations and lung cancer | Q37795807 | ||
| p95HER2 and breast cancer | Q37846003 | ||
| Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial | Q37850188 | ||
| Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. | Q38090734 | ||
| Diarrhea associated with afatinib: an oral ErbB family blocker | Q38090739 | ||
| LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both | Q38118503 | ||
| HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas | Q38474138 | ||
| HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy | Q39368710 | ||
| Afatinib (BIBW 2992) development in non-small-cell lung cancer | Q39731829 | ||
| Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance | Q40109415 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | squamous cell carcinoma | Q681817 |
| P304 | page(s) | 21-40 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck | |
| P478 | volume | 10 |
| Q33605906 | A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer |
| Q38857343 | Afatinib inhibits proliferation and invasion and promotes apoptosis of the T24 bladder cancer cell line |
| Q55509033 | Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase. |
| Q48639213 | Breakthrough targeted therapeutic approaches to squamous cell carcinoma of the head and neck |
| Q51603922 | Effects of neratinib and combination with irradiation and chemotherapy in head and neck cancer cells. |
| Q27026178 | HER2 as a therapeutic target in head and neck squamous cell carcinoma |
| Q38803544 | Inhibition of proliferation and induction of apoptosis in RB116 retinoblastoma cells by afatinib treatment |
| Q37702126 | Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma |
Search more.